These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16796796)

  • 1. A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors.
    Ahlers CM; Camphausen K; Citrin D; Arlen PM; Gulley JL
    Clin Colorectal Cancer; 2006 May; 6(1):72-5. PubMed ID: 16796796
    [No Abstract]   [Full Text] [Related]  

  • 2. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
    Gulley JL; Madan RA; Tsang KY; Arlen PM; Camphausen K; Mohebtash M; Kamrava M; Schlom J; Citrin D
    Expert Opin Biol Ther; 2011 Nov; 11(11):1409-18. PubMed ID: 21871012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRICOM: enhanced vaccines as anticancer therapy.
    Levy B; Panicalli D; Marshall J
    Expert Rev Vaccines; 2004 Aug; 3(4):397-402. PubMed ID: 15270644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
    Greiner JW; Zeytin H; Anver MR; Schlom J
    Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The carcinoembryonic antigen: apropos of an old friend].
    Téllez-Avila FI; García-Osogobio SM
    Rev Invest Clin; 2005; 57(6):814-9. PubMed ID: 16708907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
    Gulley JL; Arlen PM; Tsang KY; Yokokawa J; Palena C; Poole DJ; Remondo C; Cereda V; Jones JL; Pazdur MP; Higgins JP; Hodge JW; Steinberg SM; Kotz H; Dahut WL; Schlom J
    Clin Cancer Res; 2008 May; 14(10):3060-9. PubMed ID: 18483372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
    Chakraborty M; Abrams SI; Coleman CN; Camphausen K; Schlom J; Hodge JW
    Cancer Res; 2004 Jun; 64(12):4328-37. PubMed ID: 15205348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
    Mohebtash M; Tsang KY; Madan RA; Huen NY; Poole DJ; Jochems C; Jones J; Ferrara T; Heery CR; Arlen PM; Steinberg SM; Pazdur M; Rauckhorst M; Jones EC; Dahut WL; Schlom J; Gulley JL
    Clin Cancer Res; 2011 Nov; 17(22):7164-73. PubMed ID: 22068656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating bench with bedside: the role of vaccine therapy in the treatment of solid tumors.
    Kaufman HL
    J Clin Oncol; 2005 Feb; 23(4):659-61. PubMed ID: 15613694
    [No Abstract]   [Full Text] [Related]  

  • 14. Carcinoembryonic antigen as a target for cancer vaccines.
    Hodge JW
    Cancer Immunol Immunother; 1996 Nov; 43(3):127-34. PubMed ID: 9001565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
    Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status and progress of tumor vaccine for hepatocellular carcinoma].
    Zhou M; Yang DH
    Zhonghua Gan Zang Bing Za Zhi; 2003 Dec; 11(12):763-4. PubMed ID: 14697149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.